Sarah Hewer1, Sue Varley2, Adam L Boxer3, Eldho Paul4, David R Williams5. 1. Neurosciences Department, Alfred Hospital, Melbourne, Victoria, Australia. sarah.hewer@dhhs.tas.gov.au. 2. Neurosciences Department, Alfred Hospital, Melbourne, Victoria, Australia. 3. Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA. 4. Department of Epidemiology and Preventive Medicine, Clinical Haematology Department, Alfred Hospital, Monash University, Melbourne, Victoria, Australia. 5. Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. METHODS: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated "a little worse" and those rated "unchanged" on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. RESULTS: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. CONCLUSIONS: Clinically meaningful change is measurable on the PSPRS over 6 months.
RCT Entities:
BACKGROUND: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. METHODS: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated "a little worse" and those rated "unchanged" on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. RESULTS: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. CONCLUSIONS: Clinically meaningful change is measurable on the PSPRS over 6 months.
Authors: Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto Journal: Lancet Neurol Date: 2014-05-27 Impact factor: 44.182
Authors: Maria Stamelou; Jakob Schöpe; Stefan Wagenpfeil; Teodoro Del Ser; Jee Bang; Iryna Y Lobach; Phi Luong; Gesine Respondek; Wolfgang H Oertel; AdamL Boxer; Günter U Höglinger Journal: Mov Disord Date: 2016-03-07 Impact factor: 10.338
Authors: Maria Stamelou; Alexander Reuss; Ulrich Pilatus; Jörg Magerkurth; Petra Niklowitz; Karla M Eggert; Andrea Krisp; Thomas Menke; Carmen Schade-Brittinger; Wolfgang H Oertel; Günter U Höglinger Journal: Mov Disord Date: 2008-05-15 Impact factor: 10.338
Authors: Eduardo Tolosa; Irene Litvan; Günter U Höglinger; David Burn; Andrew Lees; María V Andrés; Belén Gómez-Carrillo; Teresa León; Teodoro Del Ser Journal: Mov Disord Date: 2014-02-14 Impact factor: 10.338
Authors: Julio C Rojas; Jee Bang; Iryna V Lobach; Richard M Tsai; Gil D Rabinovici; Bruce L Miller; Adam L Boxer Journal: Neurology Date: 2017-12-27 Impact factor: 9.910
Authors: Carmen Rodríguez-Blázquez; Maria João Forjaz; Monica M Kurtis; Roberta Balestrino; Pablo Martinez-Martin Journal: Front Neurol Date: 2018-06-07 Impact factor: 4.003
Authors: Marta F Pereira; Tim Buchanan; Günter U Höglinger; Marko Bogdanovic; George Tofaris; Simon Prangnell; Nagaraja Sarangmat; James J FitzGerald; Chrystalina A Antoniades Journal: BMJ Neurol Open Date: 2022-01-21
Authors: Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller Journal: Orphanet J Rare Dis Date: 2022-05-07 Impact factor: 4.303